A multicentre, retrospective, observational study to evaluate the effectiveness of Brentuximab vedotin in patients with transplant naive relapsed/refractory Hodgkin Lymphoma.
Latest Information Update: 26 Oct 2016
Price :
$35 *
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 26 Oct 2016 New trial record